Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Olympus Launches AI-Powered Polyp Detection System for Colonoscopies

Olympus Launches AI-Powered Polyp Detection System for Colonoscopies

Olympus, a leading medical technology company, has announced the launch of its first artificial intelligence (AI) application in the United States, marking a significant advancement in gastrointestinal (GI) endoscopy. The new AI-powered system, called Caddie, is designed to assist clinicians in detecting polyps during colonoscopies, potentially improving early diagnosis rates for colorectal cancer.

NoahAI News10/1/2025
AnaptysBio Announces Strategic Split into Two Publicly Traded Companies

AnaptysBio Announces Strategic Split into Two Publicly Traded Companies

AnaptysBio, a San Diego-based biopharmaceutical company, has unveiled plans to separate its operations into two distinct publicly traded entities. This strategic move, expected to be completed by the end of 2026, aims to maximize value for investors by creating a clear distinction between the company's clinical-stage pipeline and its royalty-based agreements.

NoahAI News10/1/2025
Novartis Secures FDA Approval for Rhapsido in Chronic Spontaneous Urticaria, Marking New Era in BTK Inhibitor Competition

Novartis Secures FDA Approval for Rhapsido in Chronic Spontaneous Urticaria, Marking New Era in BTK Inhibitor Competition

Novartis has achieved a significant milestone with the FDA's approval of Rhapsido (remibrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. This approval not only expands Novartis's portfolio in the immunology space but also sets the stage for potential competition with Sanofi in the BTK inhibitor market.

NoahAI News10/1/2025
Northwell Health's New CEO Outlines Strategy Amid Healthcare Challenges

Northwell Health's New CEO Outlines Strategy Amid Healthcare Challenges

Northwell Health, one of the largest nonprofit healthcare systems in the United States, is embarking on a new era under the leadership of John D'Angelo, M.D., who assumed the role of CEO on October 1. In an exclusive interview, D'Angelo outlined his vision for navigating the complex healthcare landscape, emphasizing growth, technology integration, and community health initiatives.

NoahAI News10/1/2025
Novo Nordisk Terminates $598M Cell Therapy Collaboration with Heartseed Amid Restructuring

Novo Nordisk Terminates $598M Cell Therapy Collaboration with Heartseed Amid Restructuring

Novo Nordisk, the Danish pharmaceutical giant, has called off its $598 million collaboration with Japanese biotech Heartseed, dealing a significant blow to the development of a promising cell therapy for advanced heart failure. This decision comes as part of Novo's company-wide restructuring efforts, which aim to refocus the firm's resources on its core diabetes and obesity businesses.

NoahAI News10/1/2025
Crystalys Therapeutics Emerges with $205M to Advance Gout Treatment

Crystalys Therapeutics Emerges with $205M to Advance Gout Treatment

Crystalys Therapeutics, a California-based biotech startup, has launched with a substantial $205 million Series A funding round to develop next-generation therapies for gout. The company's lead asset, dotinurad, is set to enter global Phase III clinical trials, building on its existing approvals in several Asian countries.

NoahAI News9/30/2025
FDA's CDER Director Sparks Controversy Over Surrogate Endpoints in Drug Approvals

FDA's CDER Director Sparks Controversy Over Surrogate Endpoints in Drug Approvals

The pharmaceutical industry is abuzz following comments made by Dr. George Tidmarsh, director of the FDA's Center for Drug Evaluation and Research (CDER), questioning the reliance on surrogate endpoints for drug approvals. In a now-deleted LinkedIn post, Tidmarsh singled out Aurinia Pharmaceuticals' lupus nephritis drug Lupkynis as an example of the potential shortcomings of this approach.

NoahAI News9/30/2025
Barinthus Bio and Clywedog Therapeutics Announce Reverse Merger, Advancing Diabetes and Autoimmune Disease Pipeline

Barinthus Bio and Clywedog Therapeutics Announce Reverse Merger, Advancing Diabetes and Autoimmune Disease Pipeline

Barinthus Biotherapeutics, a U.S.-based biotech company, has entered into a reverse merger agreement with U.K.-based Clywedog Therapeutics. The deal, announced on September 30, 2025, aims to create a combined entity focused on advancing clinical assets in diabetes and autoimmune diseases.

NoahAI News9/30/2025
Rovi Expands Manufacturing Capabilities with $250M BMS Facility Acquisition and Production Deal

Rovi Expands Manufacturing Capabilities with $250M BMS Facility Acquisition and Production Deal

Laboratorios Farmacéuticos Rovi, the Spanish contract development and manufacturing organization (CDMO), has significantly bolstered its production capacity through a landmark agreement with Bristol Myers Squibb (BMS). The deal, valued at $250 million, involves the acquisition of BMS's Phoenix facility and establishes a five-year manufacturing partnership between the two companies.

NoahAI News9/30/2025
AnaptysBio Announces Strategic Split into Two Publicly Traded Companies

AnaptysBio Announces Strategic Split into Two Publicly Traded Companies

AnaptysBio, a San Diego-based biopharmaceutical company, has unveiled plans to separate its operations into two distinct publicly traded entities. This strategic move, expected to be completed by the end of 2026, aims to maximize value for investors by creating separate focuses on clinical-stage pipeline development and royalty-based agreements.

NoahAI News9/30/2025
Opus Genetics Advances Gene Therapy for Rare Eye Disease with Promising Pediatric Data

Opus Genetics Advances Gene Therapy for Rare Eye Disease with Promising Pediatric Data

Opus Genetics, a North Carolina-based biotech company, has made significant strides in its gene therapy program for Leber congenital amaurosis type 5 (LCA5), a rare eye disease affecting approximately 200 people in the United States. The company recently shared encouraging data from its pediatric trials, setting the stage for crucial discussions with the FDA.

NoahAI News9/30/2025
Star Therapeutics Secures $125M for Von Willebrand Disease Drug Development

Star Therapeutics Secures $125M for Von Willebrand Disease Drug Development

Star Therapeutics has raised $125 million in a Series D funding round to advance its pipeline of bleeding disorder treatments, with a primary focus on its lead candidate for von Willebrand disease (VWD). The financing, co-led by Sanofi Ventures and Viking Global Investors, will support the company's ongoing Phase 3 trial of VGA039, a novel antibody therapy aimed at transforming VWD treatment.

NoahAI News9/30/2025
«1...585960...67»